Synexis’ Post

Are you having trouble with the USP <797> standards? Let us show you first hand how easy it can be to enhance your compliance. #SynesisDiversey #HealthcareSolutions #Partnership

This is innovation keeping contamination and exposure at a minimum!

While not Super Bowl ads...they are super ads from Super Companies serving pharmacy. And they are now appearing in the upcoming edition of Sterile Compounding Quality Matters (SCQM) by Pharmacy Stars edited by contributing Editor Christine Hong. First one is from the amazing EQUASHIELD® #hazardousdrugs #usp800 #pharmacystars #equashield #medicationsafety #patientsafety

#Telehealth platforms that provide diagnostic tests, pharmaceutical products, dietary supplements, or other specialty health products – as well as the clinical consultations necessary for the prescription of/recommendation for those products – exist in a unique regulatory environment. The #FTC is starting to target these platforms with #enforcement actions around alleged marketing and advertising violations, however, and the #FDA may not be far behind. Join our partners Rachael Pontikes, Emily Hussey, and Monique (Nikki) Bhargava for an engaging #CLE presentation examining the FTC and FDA regulations and guidances applicable to these sort of telehealth platforms, discussing recent enforcement actions against such platforms and what other platforms can learn from these actions, and providing a brief overview of the scope and process behind a marketing review and the protection it can offer such platforms. https://lnkd.in/epdv5phe

We're pleased to announce that this #CLE webinar is now available on demand! Join our partners Rachael Pontikes, Monique (Nikki) Bhargava, and Emily Hussey for this engaging presentation geared toward #telehealth platforms that provide diagnostic tests, pharmaceutical products, dietary supplements, or other specialty health products – as well as the clinical consultations necessary for the prescription of/recommendation for those products. These platforms exist in a unique regulatory environment, and the #FTC is starting to target them with enforcement actions around alleged marketing and advertising violations; the #FDA may not be far behind. This session examines the FTC and FDA regulations and guidances applicable to these sort of telehealth platforms, discusses recent enforcement actions against such platforms and what other platforms can learn from these actions, and provides a brief overview of the scope and process behind a marketing review and the protection it can offer such platforms. https://lnkd.in/epdv5phe

#Telehealth platforms that provide diagnostic tests, pharmaceutical products, dietary supplements, or other specialty health products – as well as the clinical consultations necessary for the prescription of/recommendation for those products – exist in a unique regulatory environment. The #FTC is starting to target these platforms with #enforcement actions around alleged marketing and advertising violations, however, and the #FDA may not be far behind. Join our partners Rachael Pontikes, Emily Hussey, and Monique (Nikki) Bhargava for an engaging #CLE presentation examining the FTC and FDA regulations and guidances applicable to these sort of telehealth platforms, discussing recent enforcement actions against such platforms and what other platforms can learn from these actions, and providing a brief overview of the scope and process behind a marketing review and the protection it can offer such platforms. https://lnkd.in/epdv5phe

🌟 Exciting Developments in Compounding Safety and Quality 🌟 Recently, I stumbled upon an insightful article discussing the dynamic landscape of sterile compounding safety. My pal (and former boss 😁), Kevin Hansen, PharmD, highlighted that the updated USP General Chapters <797> and <800> serve as the foundation for ensuring sterile compounding safety. At CriticalPoint, we echo Kevin's sentiment, advocating for organizations to transcend mere compliance and foster a culture of continuous improvement. A crucial recommendation put forth by Dr. Hansen is for facilities preparing compounded sterile preparations to carefully review the FDA's 2020 guidance document on Insanitary Conditions at Compounding Facilities. This document sets forth conditions that should never be present, exceeding the requirements outlined in USP <797>. As dedicated professionals in the field, let's heed Dr. Hansen's insights and strive for excellence in sterile compounding. Together, let's pursue innovative ways to enhance patient outcomes and uphold the highest standards of safety and quality. #compoundingsafety #continuousimprovement #patientcare #pharmacyexcellence #compoundingpharmacy #patientsafety #pharmacists #pharmacytechnicians

It's your last opportunity to register for our free webinar using the link in the post below. Unlock the full potential of USP 795 compliance!

Are you navigating the complexities of running a pharmacy with all of today’s challenges? Watch “Pharmacy Profitability in Challenging Times” and discover strategies from Inmar Intelligence to boost your bottom line! https://hubs.li/Q02NQX9h0

Excited to have Dr. Del Doherty presenting at #SIGFA2024! Join us for 'Demystifying Pharmacy Spend Part II: Understanding the Cost Side of the Equation' for invaluable insights into pharmacy cost management. See you there! #pharmacymanagement #SIGFA